Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
1.410 ^USD	0.00%		+6.02%	+4.44%

09/02	Ocugen appoints Rita Johnson-Greene to chief financial officer	RE
23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT

Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 11/05/2025 at 10:51 pm IST - Modified on 11/05/2025 at 08:12 pm IST

S&P Capital IQ

OCUGEN, INC.

0.00%

MEDTECH SOLUTIONS S.A.

+12.78%

Ocugen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 1.75 million compared to USD 1.14 million a year ago. Net loss was USD 20.05 million compared to USD 12.97 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.05 a year ago.
For the nine months, revenue was USD 4.61 million compared to USD 3.29 million a year ago. Net loss was USD 50.14 million compared to USD 40.17 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to USD 0.15 a year ago.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	OCUGEN, INC.	1.410USD	0.00%	+6.02%	46Cr
	MEDTECH SOLUTIONS S.A.	0.4060PLN	+12.78%	+14.04%	86.38L

Latest news about Ocugen, Inc.

09/02	Ocugen appoints Rita Johnson-Greene to chief financial officer	RE
23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT
21/01	Ocugen Prices $22.5 Million Stock Offering	MT
15/01	Ocugen, Inc. - Special Call
15/01	Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial	MT
15/01	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
15/01	Ocugen announces positive preliminary phase 2 data from Ocu410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration	RE
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
05/11	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
05/11	Biotech firm Ocugen's Q3 revenue beats expectations	RE
18/25/18	Ocugen Inc says on Sept 16, carisma terminates merger agreement with Ocugen	RE
15/25/15	Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong	MT
15/25/15	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
13/25/13	Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy	RE
09/25/09	Ocugen announces $20 million registered direct offering of common stock and warrants	RE

Chart Ocugen, Inc.

Duration

Period

OCGN: Dynamic Chart

Company Profile

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

Calendar

31/07 - Q2 2026 Earnings Release (Projected)

More about the company